论文部分内容阅读
目的:观察重组人血管内皮抑制素联合胸腔内化疗治疗难治性恶性胸腔积液的疗效和安全性。方法:27例胸腔内化疗后失败的恶性胸腔积液患者,接受重组人血管内皮抑制素30 mg联合化疗药物胸腔内注射,每周2次,共2～3周,评价治疗结束4周疗效、KPS评分变化和不良反应。结果:11例患者治疗后病情控制良好,有效率为40.7%,15例患者KPS评分改善(55.6%)。疗效达完全缓解和部分缓解患者的KPS评分改善率明显高于疗效为疾病稳定和疾病进展患者(37.0%比18.5%,P=0.03)。不良反应少见,且与重组人血管内皮抑制素无关,未观察到3～4级不良反应。结论:重组人血管内皮抑制素联合化疗治疗难治性恶性胸腔积液的疗效肯定,安全性良好。
Objective: To observe the efficacy and safety of recombinant human endostatin combined with intrathoracic chemotherapy in the treatment of refractory malignant pleural effusion. Methods: Twenty-seven patients with malignant pleural effusion who failed after thoracic chemotherapy received thoracic injection of recombinant human endostatin 30 mg combined with chemotherapeutic drugs twice a week for 2 to 3 weeks to evaluate the efficacy of the treatment for 4 weeks. KPS score changes and adverse reactions. Results: After treatment, 11 patients were well controlled with an effective rate of 40.7% and 15 patients with improved KPS score (55.6%). Patients treated with complete remission and partially remission experienced significantly better KPS scores than patients with stable disease and disease progression (37.0% vs 18.5%, P = .03). Adverse reactions were rare, and had nothing to do with recombinant human endostatin, 3 to 4 adverse reactions were not observed. Conclusion: Recombinant human endostatin combined with chemotherapy for the treatment of refractory malignant pleural effusion has a positive effect and good safety.